Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ActiProct Gel is a topical medical device developed and marketed by Adcock Ingram for the relief of symptoms associated with Grade I and II hemorrhoids (piles). The product's primary active component is the 2QR-complex, a natural polysaccharide complex derived from *Aloe barbadensis*. Unlike traditional pharmaceutical drugs that target specific biological pathways, ActiProct Gel operates through a physical mechanism of action. It creates a protective barrier that prevents pathogenic bacteria from contacting the tissue, thereby reducing inflammation and supporting the natural healing process. Additionally, the gel provides a lubricating and cooling effect to alleviate itching, irritation, pain, and burning. It is approved for rectal use and is considered safe for use during pregnancy and breastfeeding.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ActiProct Gel.